OpenAI released Rosalind Workbench, a unified environment that consolidates fragmented scientific tools and data into one workspace for life science researchers. It's built on GPT-Rosalind, a specialized model for biology, and available through ChatGPT with guided workflows for tasks like protein design, genomics analysis, and molecular docking.

• Solves a real workflow problem: researchers currently juggle data in one system, analysis in another, and experimental records elsewhere, losing context between steps
• Includes specialized viewers and guided tasks (protein design, small-molecule design, genomics, experimental validation) that keep biological questions connected across different tools
• Offers two access modes—Explore mode for general questions and Research mode for complex analysis, with verified organizations able to request access now and individual access coming later

Anthropic has kicked off an internal drug discovery effort focused on neglected diseases to sharpen its AI tools for biopharma clients. By running its own research alongside partners, the company aims to gather feedback and demonstrate Claude Science’s capabilities.

• Anthropic is running its own internal drug discovery program targeting neglected diseases to battle-test and improve Claude Science before selling it to pharma partners.
• As a public benefit company, Anthropic claims it can choose projects based on patient need rather than commercial potential, unlike typical biotechs.
• The company hasn't said what happens if it finds a promising drug candidate, leaving unclear how it would handle clinical trials.
• This follows a mixed track record for big tech in healthcare, including Alphabet's life sciences unit, Apple's health features, and Amazon's One Medical/PillPack acquisitions.